摘要
目的针对多西他赛(TXT)联合希罗达(Xeloda)在晚期胃癌病患中的临床疗效进行试验观察统计分析。方法将2006年6月～2011年12月收治的82例患者随机平均分为治疗组41例,应用多西他赛联合希罗达治疗;对照组41例应用奥沙利铂(LOHP)联合希罗达(Xeloda)治疗,均进行9周期以上化疗。结果治疗组治疗有效率(CR+PR)为53.7%,CR6例,PR16例,SD15例,PD4例;对照组治疗有效率为56.1%,CR5例,PR18例,SD14例,PD4例;数据间差异无统计学意义(P>0.05)。两组均无过敏反应和极少肝肾功能损伤、手足综合征发生,主要表现为骨髓抑制和胃肠道反应,数据差异无统计学意义(P>0.05);在外周神经毒性中,治疗组为22.0%,对照组为61.0%,差异有统计学意义(P<0.05),治疗组优于对照组。结论两种方案对晚期胃癌患者疗效相当,不良反应可以耐受,在外周神经毒性中治疗组优于对照组。
Objective To evalulate the therapeutic effect of TXT combined with Xeloda for advanced gastric cancer. Methods 82 patients with advanced gastric cancer taken into the hospital during Jun 2006 to Dec 2011 ,were randomized and divided into two groups. Group 1 consisted of 41 patients got Docetaxe combined with Xeloda and group 2 with 41 patients received Oxaliplatin combined with Xeloda.The treatment was lasted 6 weeks. Results In group 1 and 2 ,the effective treatment rate （CR ＋ PR） was 53.7 % and 56.1% （P〉0.05）. There was no particular adverse effect,such as anaphylaxis, hepatic or kidney injury and hand-foot syndrome,the most common ones were myelosuppression and gastrointestinal response in each group（P〉0.05）; the rate of mild neurotoxicity of the 2 groups were 22.0%in group 1, 61.0% in group 2 （P〈0.05）. Conclusion The therapeutic effect of docetaxe combined with Xeloda for advanced gastric cancer were comparable and annronriate with a well tcderance
出处
《当代医学》
2012年第10期6-7,共2页
Contemporary Medicine
关键词
多西他赛
希罗达
奥沙利铂
胃癌
Docetaxe
Oxaliplatin
Xeloda
Advanced Gastric .Cancer
